<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="article-commentary" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">105511</article-id><article-id pub-id-type="doi">10.7554/eLife.105511</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Insight</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group><subj-group subj-group-type="sub-display-channel"><subject>Opioids</subject></subj-group></article-categories><title-group><article-title>Finding new ways to treat overdoses</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Turner</surname><given-names>Jill R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7258-1639</contrib-id><email>jill.turner@uky.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/><bio><p><bold>Jill R Turner</bold> is in the Department of Pharmaceutical Sciences, University of Kentucky, Lexington, United States</p></bio></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Jocelyn</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0006-7112-5101</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/><bio><p><bold>Jocelyn Martin</bold> is in the Department of Pharmaceutical Sciences, University of Kentucky, Lexington, United States</p></bio></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02k3smh20</institution-id><institution>Department of Pharmaceutical Sciences, University of Kentucky</institution></institution-wrap><addr-line><named-content content-type="city">Lexington</named-content></addr-line><country>United States</country></aff></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>27</day><month>01</month><year>2025</year></pub-date><volume>14</volume><elocation-id>e105511</elocation-id><permissions><copyright-statement>© 2025, Turner and Martin</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Turner and Martin</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-105511-v1.pdf"/><related-article related-article-type="commentary-article" ext-link-type="doi" xlink:href="10.7554/eLife.104469" id="ra1"/><abstract><p>Reversing opioid overdoses in rats using a drug that does not enter the brain prevents the sudden and severe withdrawal symptoms associated with therapeutics that target the central nervous system.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>opioids</kwd><kwd>fentanyl</kwd><kwd>overdose</kwd><kwd>naloxone</kwd><kwd>naloxone methiodide</kwd><kwd>withdrawal</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Rat</kwd></kwd-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Reversing opioid overdoses in rats using a drug that does not enter the brain prevents the sudden and severe withdrawal symptoms associated with therapeutics that target the central nervous system.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Template</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text><p><bold>Related research article</bold> Ruyle BC, Sarah M, Rohith K, Mubariz T, Juhi M, Caroline R, Sofia AL, Tania L, Higginbotham Jessica A, Nicolas M, Moron Jose A. 2024. Peripheral opioid receptor antagonism alleviates fentanyl-induced cardiorespiratory depression and is devoid of aversive effects. <italic>eLife</italic> <bold>13</bold>:RP104469. doi: <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.7554/eLife.104469">10.7554/eLife.104469</ext-link>.</p></boxed-text><p>While the societal and human cost of opioid use disorder is now widely recognized, there are still few evidence-based interventions to treat those experiencing addiction, including strategies for the prevention of overdoses. The gold standard rescue agent for opioid overdose remains naloxone – a life-saving drug now available over the counter (<xref ref-type="bibr" rid="bib4">FDA, 2023</xref>), which works by binding to mu opioid receptors (known as MORs) in the brain and abruptly disrupting their signaling.</p><p>However, those treated with naloxone often report that being rescued from an overdose was a highly traumatic, painful experience. The treatment triggers immediate and severe withdrawal symptoms, including vomiting, diarrhea, abdominal, bone and muscle pain, altered consciousness, elevated heart rate, and agitation (<xref ref-type="bibr" rid="bib6">Hassanian-Moghaddam et al., 2014</xref>; <xref ref-type="bibr" rid="bib8">Lai et al., 2021</xref>).</p><p>MORs are found across the central nervous system and are highly enriched in certain brain areas (<xref ref-type="bibr" rid="bib9">Le Merrer et al., 2009</xref>) that are known to control multiple aspects of opioid overdose, such as respiratory depression (<xref ref-type="bibr" rid="bib13">Vázquez-León et al., 2021</xref>; <xref ref-type="bibr" rid="bib1">Aicher et al., 2000</xref>). This decrease in, or complete loss of, breathing is the leading cause of opioid-related death (<xref ref-type="bibr" rid="bib14">Zedler et al., 2018</xref>).</p><p>However, physical access to MORs in the brain is regulated by the blood-brain barrier – a selective, semi-permeable membrane that separates the central nervous system from the rest of the body (<xref ref-type="bibr" rid="bib2">Ballabh et al., 2004</xref>). Although naloxone can cross this barrier, many compounds cannot, and this has been a key stumbling block for drug development (<xref ref-type="bibr" rid="bib10">Pardridge, 2005</xref>). Now, in eLife, Jose Moron and colleagues at Washington University in St. Louis – including Brian Ruyle as first author – report that blocking MORs outside the brain can reverse opioid overdoses in rats without inducing the severe withdrawal symptoms associated with naloxone (<xref ref-type="bibr" rid="bib11">Ruyle et al., 2024</xref>).</p><p>First, Ruyle et al. investigated the precise mechanisms underlying opioid-induced respiratory depression. Administering the synthetic opioid fentanyl to rats lowered their oxygen saturation measurements, confirming that it induces respiratory depression (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The experiments also revealed that fentanyl increases the activity of neurons in an area of the brain called the nucleus of the solitary tract, in a dose-dependent manner. This area contains many MORs and heavily regulates breathing as it is the first to place to receive sensory information about oxygen levels (<xref ref-type="bibr" rid="bib3">Baptista et al., 2005</xref>; <xref ref-type="bibr" rid="bib1">Aicher et al., 2000</xref>; <xref ref-type="bibr" rid="bib15">Zhuang et al., 2017</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Blocking opioid receptors outside the brain reverses opioid overdose without sudden and severe withdrawal symptoms.</title><p>(<bold>A</bold>) The synthetic opioid fentanyl can inhibit breathing (known as respiratory depression) in people who use the drug. Experiments by Ruyle et al. that measured blood oxygen levels confirmed that fentanyl has the same effect on rats. (<bold>B</bold>) The gold standard medicine for treating opioid overdoses is naloxone (left), a drug that crosses the blood-brain barrier and binds to opioid receptors in the central nervous system. This rescues respiratory depression but leads to sudden and severe withdrawal symptoms, which patients report as traumatic. Ruyle et al. explored whether an alternative compound called naloxone methiodide (right), which binds to opioid receptors but cannot cross the blood-brain barrier, can rescue respiratory depression without inducing the negative side effects associated with naloxone. (<bold>C</bold>) To test this, Ruyle et al. treated rats that had been administered fentanyl with either naloxone or naloxone methiodide. Both treatments successfully reversed the fentanyl-induced respiratory depression. A conditioned place aversion experiment was used to test whether either of the treatments caused distressing symptoms. Rats treated with naloxone showed aversion to the compartment in which they were treated, whereas rats treated with naloxone-methiodide did not display aversion. This suggests that naloxone-methiodide can rescue respiratory depression without the negative side effects induced by naloxone, representing a potential new therapeutic avenue to explore in humans. This figure was created with <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/a29x251">BioRender.com</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105511-fig1-v1.tif"/></fig><p>With this knowledge, Ruyle et al. next assessed whether an MOR antagonist called naloxone-methiodide (which is derived from naloxone but does not cross the blood-brain barrier) could rescue fentanyl-induced respiratory depression (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Treating rats with naloxone-methiodide either before or after administering fentanyl successfully prevented or reversed respiratory depression, respectively. This approach of blocking MORs outside the brain was as effective as naloxone treatment, without the requirement of crossing the blood-brain barrier (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). In tandem, Ruyle et al. also used immunofluorescence and a technique called fiber photometry to demonstrate that blocking peripheral opioid receptors affected the fentanyl-induced activity of the nucleus of the solitary tract neurons, revealing a mechanism behind naloxone-methiodide’s action.</p><p>The most striking finding described by Ruyle et al. came when they used an approach called ‘conditioned place aversion’ to assess if blocking peripheral MORs reduces the severity of the withdrawal symptoms. In this procedure, rats were given fentanyl in one compartment and then treated with naloxone or naloxone-methiodide in another. Afterwards, the rats treated with naloxone showed aversion to the compartment in which they had been treated, suggesting that their experience had been distressing. However, those treated with naloxone-methiodide did not exhibit this behavior, suggesting that the treatment, while effective as a respiratory depression rescue agent, also did not cause unpleasant withdrawal symptoms (<xref ref-type="fig" rid="fig1">Figure 1C</xref>).</p><p>Taken together, the findings highlight a new therapeutic avenue to address opioid overdose without eliciting distressing withdrawal symptoms. This approach could be highly beneficial for harm reduction in opioid use disorder, given that many clinical reports show that the effects of naloxone-mediated withdrawal can lead to a reluctance to administer it in overdose scenarios (<xref ref-type="bibr" rid="bib5">Hall et al., 2024</xref>). Furthermore, concerns about treatment-induced withdrawal symptoms are often a reason for individuals not seeking other evidence-based treatment for opioid use disorder (<xref ref-type="bibr" rid="bib12">Spadaro et al., 2022</xref>; <xref ref-type="bibr" rid="bib7">Kosten and Baxter, 2019</xref>). This important work by Ruyle et al. reframes our understanding of successful overdose rescue and could lead to future treatments with reduced withdrawal effects.</p></body><back><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aicher</surname><given-names>SA</given-names></name><name><surname>Goldberg</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Pickel</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>mu-opioid receptors are present in vagal afferents and their dendritic targets in the medial nucleus tractus solitarius</article-title><source>The Journal of Comparative Neurology</source><volume>422</volume><fpage>181</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1002/(sici)1096-9861(20000626)422:2&lt;181::aid-cne3&gt;3.0.co;2-g</pub-id><pub-id pub-id-type="pmid">10842226</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballabh</surname><given-names>P</given-names></name><name><surname>Braun</surname><given-names>A</given-names></name><name><surname>Nedergaard</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The blood-brain barrier: an overview: structure, regulation, and clinical implications</article-title><source>Neurobiology of Disease</source><volume>16</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2003.12.016</pub-id><pub-id pub-id-type="pmid">15207256</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baptista</surname><given-names>V</given-names></name><name><surname>Zheng</surname><given-names>ZL</given-names></name><name><surname>Coleman</surname><given-names>FH</given-names></name><name><surname>Rogers</surname><given-names>RC</given-names></name><name><surname>Travagli</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Characterization of neurons of the nucleus tractus solitarius pars centralis</article-title><source>Brain Research</source><volume>1052</volume><fpage>139</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2005.05.073</pub-id><pub-id pub-id-type="pmid">16005442</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="report"><person-group person-group-type="author"><collab>FDA</collab></person-group><year iso-8601-date="2023">2023</year><source>FDA approves first over-the-counter naloxone nasal spray</source><publisher-name>U.S. Food and Drug Administration</publisher-name><ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-naloxone-nasal-spray">https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-naloxone-nasal-spray</ext-link></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>OT</given-names></name><name><surname>Entrup</surname><given-names>P</given-names></name><name><surname>Farabee</surname><given-names>K</given-names></name><name><surname>Qin</surname><given-names>H</given-names></name><name><surname>Rizvi</surname><given-names>H</given-names></name><name><surname>Rausch</surname><given-names>J</given-names></name><name><surname>Felkel</surname><given-names>WC</given-names></name><name><surname>Teater</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>The perceived role of withdrawal in maintaining opioid addiction among adults with untreated opioid use disorder: A survey of syringe exchange program participants</article-title><source>Substance Use &amp; Misuse</source><volume>59</volume><fpage>312</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1080/10826084.2023.2269571</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassanian-Moghaddam</surname><given-names>H</given-names></name><name><surname>Afzali</surname><given-names>S</given-names></name><name><surname>Pooya</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Withdrawal syndrome caused by naltrexone in opioid abusers</article-title><source>Human &amp; Experimental Toxicology</source><volume>33</volume><fpage>561</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1177/0960327112450901</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosten</surname><given-names>TR</given-names></name><name><surname>Baxter</surname><given-names>LE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment</article-title><source>The American Journal on Addictions</source><volume>28</volume><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1111/ajad.12862</pub-id><pub-id pub-id-type="pmid">30701615</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>JT</given-names></name><name><surname>Goldfine</surname><given-names>CE</given-names></name><name><surname>Chapman</surname><given-names>BP</given-names></name><name><surname>Taylor</surname><given-names>MM</given-names></name><name><surname>Rosen</surname><given-names>RK</given-names></name><name><surname>Carreiro</surname><given-names>SP</given-names></name><name><surname>Babu</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Nobody wants to be Narcan’d: A pilot qualitative analysis of drug users’ perspectives on naloxone</article-title><source>The Western Journal of Emergency Medicine</source><volume>22</volume><fpage>339</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.5811/westjem.2020.10.48768</pub-id><pub-id pub-id-type="pmid">33856321</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Merrer</surname><given-names>J</given-names></name><name><surname>Becker</surname><given-names>JAJ</given-names></name><name><surname>Befort</surname><given-names>K</given-names></name><name><surname>Kieffer</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Reward processing by the opioid system in the brain</article-title><source>Physiological Reviews</source><volume>89</volume><fpage>1379</fpage><lpage>1412</lpage><pub-id pub-id-type="doi">10.1152/physrev.00005.2009</pub-id><pub-id pub-id-type="pmid">19789384</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardridge</surname><given-names>WM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The blood-brain barrier: bottleneck in brain drug development</article-title><source>NeuroRx</source><volume>2</volume><fpage>3</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1602/neurorx.2.1.3</pub-id><pub-id pub-id-type="pmid">15717053</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruyle</surname><given-names>BC</given-names></name><name><surname>Sarah</surname><given-names>M</given-names></name><name><surname>Rohith</surname><given-names>K</given-names></name><name><surname>Mubariz</surname><given-names>T</given-names></name><name><surname>Juhi</surname><given-names>M</given-names></name><name><surname>Caroline</surname><given-names>R</given-names></name><name><surname>Sofia</surname><given-names>AL</given-names></name><name><surname>Tania</surname><given-names>L</given-names></name><name><surname>Higginbotham Jessica</surname><given-names>A</given-names></name><name><surname>Nicolas</surname><given-names>M</given-names></name><name><surname>Moron Jose</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Peripheral opioid receptor antagonism alleviates fentanyl-induced cardiorespiratory depression and is devoid of aversive effects</article-title><source>eLife</source><volume>13</volume><elocation-id>RP104469</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.104469</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spadaro</surname><given-names>A</given-names></name><name><surname>Sarker</surname><given-names>A</given-names></name><name><surname>Hogg-Bremer</surname><given-names>W</given-names></name><name><surname>Love</surname><given-names>JS</given-names></name><name><surname>O’Donnell</surname><given-names>N</given-names></name><name><surname>Nelson</surname><given-names>LS</given-names></name><name><surname>Perrone</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Reddit discussions about buprenorphine associated precipitated withdrawal in the era of fentanyl</article-title><source>Clinical Toxicology</source><volume>60</volume><fpage>694</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1080/15563650.2022.2032730</pub-id><pub-id pub-id-type="pmid">35119337</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vázquez-León</surname><given-names>P</given-names></name><name><surname>Miranda-Páez</surname><given-names>A</given-names></name><name><surname>Chávez-Reyes</surname><given-names>J</given-names></name><name><surname>Allende</surname><given-names>G</given-names></name><name><surname>Barragán-Iglesias</surname><given-names>P</given-names></name><name><surname>Marichal-Cancino</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The periaqueductal gray and its extended participation in drug addiction phenomena</article-title><source>Neuroscience Bulletin</source><volume>37</volume><fpage>1493</fpage><lpage>1509</lpage><pub-id pub-id-type="doi">10.1007/s12264-021-00756-y</pub-id><pub-id pub-id-type="pmid">34302618</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zedler</surname><given-names>BK</given-names></name><name><surname>Saunders</surname><given-names>WB</given-names></name><name><surname>Joyce</surname><given-names>AR</given-names></name><name><surname>Vick</surname><given-names>CC</given-names></name><name><surname>Murrelle</surname><given-names>EL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Validation of a screening risk index for serious prescription opioid-induced respiratory depression or overdose in a US commercial health plan claims database</article-title><source>Pain Medicine</source><volume>19</volume><fpage>68</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1093/pm/pnx009</pub-id><pub-id pub-id-type="pmid">28340046</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mu-opioid receptors in the caudomedial NTS are critical for respiratory responses to stimulation of bronchopulmonary C-fibers and carotid body in conscious rats</article-title><source>Respiratory Physiology &amp; Neurobiology</source><volume>235</volume><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.resp.2016.10.004</pub-id><pub-id pub-id-type="pmid">27743812</pub-id></element-citation></ref></ref-list></back></article>